Human AB Serum (HABS) has officially moved from “helpful reagent” to “regulated input.” FDA and EMA inspections are now scrutinizing HABS with the same rigor applied to drug-substance components — and for good reason. Gaps in donor eligibility, viral safety, or pooling strategy can ripple through manufacturing, jeopardizing product quality, patient safety, and regulatory timelines.
In a special report authored by our VP, Troy Fugate, in collaboration with Gemini, we dive into:
What inspectors ask first: donor qualification, pooling logic, viral safety, lineage, and specifications.
Common pitfalls: weak viral safety rationales, unclear pooling, thin change-control processes.
What “good” looks like: building a raw-material file, supplier lifecycle management, and bridging discipline.
Global alignment: FDA, EMA, MHRA, and USP frameworks are converging on one expectation — treat ancillary materials as if they were critical raw materials.
Bottom line: HABS oversight is now a bellwether for overall CMC maturity. Programs that demonstrate end-to-end control sail through inspections. Those relying only on certificates face preventable findings and costly delays.
